Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Difluprednate in Anterior Uveitis
NCT00405496Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2000
- Sponsor
- Sirion Therapeutics, Inc.
- Modality
- Orthosteric Ligands
- Drugs
- difluprednate
- Conditions
- anterior uveitis (AU)
01
Overview
Phase 2, randomised, double-blind trial of difluprednate in anterior uveitis (AU) (2 arms), sponsored by Sirion Therapeutics, Inc. Primary endpoint: Anterior Chamber Cell Score at 14 days. Started Mar 2000; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Difluprednate 0.05%
Difluprednate Ophthalmic Emulsion 0.05%
Rinderon
Rinderon (0.1% betamethasone sodium phosphate)
03
Endpoints
Primary
Anterior Chamber Cell Score
Secondary
Flare Value
Anterior Chamber Flare
Clinical Signs and Symptoms
Beyond the preview
Go deeper on NCT00405496.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00405496.